医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Meiji Seika Pharma Sets up a New Subsidiary in the US

2021年01月05日 AM10:00
このエントリーをはてなブックマークに追加


 

TOKYO

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi, “Meiji”) today announces the starting of operation of its US subsidiary, Meiji Pharma USA Inc., for expanding activities in the US with its initial focus on facilitating clinical development.

Outline of the new company
(1) Company name: Meiji Pharma USA Inc.

(2) Location: 500 Frank W. Burr Boulevard, Teaneck, NJ 07666
(3) President: Yasushi Miyazawa
(4) Scope of business: Clinical research and development
(5) Paid in capital: US$100,000.

(6) Established: 4 July, 2020
(7) Shareholding structure: Wholly-owned by Meiji Seika Pharma Co., Ltd.

Meiji Seika Pharma, since it launched penicillin in Japan in 1946, has been providing high-quality pharmaceutical products such as antibiotics, antidepressants and antipsychotics in Japan and overseas. As a “Speciality & Generic Pharmaceutical Company”, Meiji focuses its pharmaceutical business on infectious disease, central nervous system disorders, and generic drugs as well.

(URL: https://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/)
Meiji Pharma USA, in collaboration with Meiji, strives for meeting the medical needs and contributes to the well-being of people worldwide.

* Integrated Reports:
https://www.meiji.com/global/investors/results-and-presentations/integrated-reports/

View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005226/en/

CONTACT

Meiji Pharma USA Inc.

Yasushi Miyazawa

President

Telephone: +1-201-777-7133

E-mail: pr-pharma@meiji.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists